Antipodes Partners LTD Vertex Pharmaceuticals Inc Transaction History
Antipodes Partners LTD
- $2.72 Billion
- Q2 2024
A detailed history of Antipodes Partners LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Antipodes Partners LTD holds 127,295 shares of VRTX stock, worth $64 Million. This represents 2.2% of its overall portfolio holdings.
Number of Shares
127,295
Previous 189,400
32.79%
Holding current value
$64 Million
Previous $78.2 Million
23.69%
% of portfolio
2.2%
Previous 2.47%
Shares
3 transactions
Others Institutions Holding VRTX
# of Institutions
1,716Shares Held
225MCall Options Held
1.19MPut Options Held
1.56M-
Capital World Investors Los Angeles, CA26.7MShares$13.4 Billion2.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA23MShares$11.5 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.7 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.7MShares$5.89 Billion0.24% of portfolio
-
Capital Research Global Investors Los Angeles, CA8.54MShares$4.29 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $129B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...